Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy

Cancers

HiddeJ. Haisma¹  OliviaA. Diaz Arguello¹ 

[1] Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, 9713AV Groningen, The Netherlands;

关键词: cancer;    apoptosis;    TNF family;    death receptors;   

DOI  :  10.3390/cancers13071543

来源: DOAJ

【 摘 要 】

Cancer is a complex disease with apoptosis evasion as one of its hallmarks; therefore, apoptosis induction in transformed cells seems a promising approach as a cancer treatment. TNF apoptosis-inducing ligands, which are naturally present in the body and possess tumoricidal activity, are attractive candidates. The most studied proteins are TNF-α, FasL, and TNF-related apoptosis-inducing ligand (TRAIL). Over the years, different recombinant TNF family-derived apoptosis-inducing ligands and agonists have been designed. Their stability, specificity, and half-life have been improved because most of the TNF ligands have the disadvantages of having a short half-life and affinity to more than one receptor. Here, we review the outlook on apoptosis-inducing ligands as cancer treatments in diverse preclinical and clinical stages and summarize strategies of overcoming their natural limitations to improve their effectiveness.

【 授权许可】

Unknown